[111In]-octreotide scintigraphy has a higher sensitivity for tumour detection, and is supersyndromes multiple endocrine neoplasia (MEN-I) and Zollinger-Ellison syndrome (ZES) were examined ior to MR imaging and CT scanning in the identification of previously unsuspected extraliver and lymph with 111In-DTPA-D-Phe1-octreotide. Scintigrams were obtained at 24 and 48 h, and the results were node metastases. It may also be helpful for the localization of clinically suspected tumours in compared with CT and magnetic resonance imaging (MRI). Thirty-five of 48 patients had positive [111In]-patients with MEN-I and ZES.
Introduction
Primary neuroendocrine tumours (NETs) are often scanning is highly accurate and non-invasive. MRI has been shown to be effective for detecting tumours in small and grow slowly. This often makes their identification and localization difficult, especially in both the liver and pancreas and is more sensitive than CT.2,3 However, these techniques also have limitations the early stages. NETs in the gastroenteropancreatic system are especially difficult to localize, due to for localizing and staging tumours. For CT scanning to be useful for the detection of NETs, advanced dynamic their anatomical and multiple functional characteristics. Unfortunately, metastases are already present scanning techniques with rapid contrast injection are required. Contrast enhancement of the peritumour at the time of diagnosis in most cases.1 For both diagnosis and management purposes, identification vessels permits identification of tumour involvement of the adjacent arterial and venous structures, and also of the primary tumour and metastases is mandatory.
Conventional radiological techniques such as comidentifies tumours greater than 2 cm in diameter and metastases of regional lymph nodes or in the liver. puted tomography (CT), magnetic resonance imaging (MRI), and angiography are well established as Approximately 30-75% of solitary gastrinomas may be detected at CT scanning.4 However, the pancreas advanced tools for the identification of NETs. CT is one of the most difficult abdominal organs to surgical resection of a primary tumour had recurrent visualize, even by MR imaging. Although pancreatic disease: metastatic liver disease was found in 18 endocrine tumours have significantly longer T1 and T2 patients, mediastinal metastases in four patients, relaxation times compared to normal pancreas tissue, abdominal and/or pelvic lymph nodes in three the potential advantage of the improved tissue contrast patients, and bony metastases in four patients. All of MR imaging has been overshadowed by the pres-37 patients underwent hormone marker evaluation ence of motion artifacts. Because of these, small panby radioimmunoassay. Besides urinary 5-HIAA and creatic endocrine tumours are not detected, and the 5-HT, plasma pancreastatin, neurokinin A, pancreatic sensitivity is less than 50%.5 Because pancreatic endopolypeptide, gastrin, insulin, vasoactive intestinal crine tumours are frequently vascular, contrast agents peptide, glucagon and somatostatin were analysed such as gadolinium-DTPA can improve imaging. A in carcinoid and PET patients. Plasma calcitonin, report by Semelke has suggested that MR imaging with calcitonin-gene-related peptide and pancreatic polydynamic gadolinium enhancement and fat suppression peptide were measured in MCT patients. may be superior to CT in detecting small (<1.5 cm in
In addition, in another group of 11 patients, the diameter) pancreatic tumours.6 In addition, a major diagnosis of multiple endocrine neoplasia type I drawback of CT scanning and MR imaging is that only (MEN-I) (n=3) and Zollinger-Ellison syndrome (ZES) suspected specific anatomical sites such as the abdo-(n=8) were based on the clinical features, family men or chest are usually imaged.
history and elevated hormone levels. The clinical The recent observation that the cell surfaces of characteristics of these patients are presented in NETs express somatostatin receptors has led to the liver/pancreas, peritoneal cavity) water was used in women and 11 men); 9 patients with pancreatic preference to oral contrast. endocrine tumours (PETs) (3 gastrinomas, 2 insu-MR imaging was performed on a Sigma 1.5 T linomas, 1 VIPoma and 3 tumours of undetermined MRS 1000 superconducting imaging system (GE). In type; 4 women and 5 men); and 3 patients with each patient, two pulse sequences were employed: metastatic medullary carcinoma of thyroid (MCTs) (1 a T1-weighted spin-echo (SE) sequence and a T2-woman and 2 men). The mean age of the patients weighted SE sequence. Additional T2-weighted SE was 56.1 years (range 6-78 years). Thirty-three images of patients were obtained immediately after patients had had the primary tumours surgically a bolus intravenous administration of 0.1 mmol/kg removed, and four patients had the histopathological Gadopentetate with a 10 mm section thickness and diagnosis established by ultrasound-guided biopsy. At the time of the study, 28 patients who underwent a 5.0 or 10 mm intersection gap. 
Results

Patients
Carcinoid tumours
Primary and metastatic lesions were identified by CT and MR imaging in 19/25 patients with proven carcinoid tumours. Of these 19 patients, 18 had positive [111In]-octreotide scintigraphy. The false negative Octreoscan patient had both the symptoms and the biochemical evidence of a metastatic neuroendocrine tumour, and three metastatic lesions in the liver (diameter varied from 1-4 cm) which were detected by MR imaging and CT scanning. Apart from the visualization of known lesions, previously unrecognized sites were found in 9/19 patients by scintigraphy. In the remaining six of the 25 patients, five were found to have previously unsuspected liver, para-aortic lymph node, pulmonary or bone lesions on scintigraphy, which were not identified using conventional imaging techniques. The diagnosis was subsequently confirmed surgically in two patients, and on percutaneous needle biopsy in three. In one further patient with resected carcinoid tumours of the ileum, Octreoscan, MR imaging and CT scanning were concordantly negative.
Pancreatic endocrine tumours (PETs)
Eight of nine patients with primary or metastatic pancreatic endocrine tumours had positive scintigraphy, but liver metastases in one patient with histologically-proven insulinoma remained undetected. One patient with a previously resected pancreatic VIPoma demonstrated widespread metastases in a b both lobes of the liver by all imaging procedures revealed the pancreatic and liver lesions, but no lymph-node abnormality. Biopsy subsequent to the scintigrams showed a neuroendocrine tumour in the pancreas secreting insulin, gastrin and glucagon, widespread metastatic lesions in the liver and multiple extra-liver lymph-node metastases.
Medullary carcinoma of the thyroid (MCT )
Three MCT patients, with multiple liver and mediastinal lymph-node involvement identified on MR imaging and CT scanning had negative octreotide scintigraphy, the only identified lesion was a probable small-bone metastasis.
In the remaining 11 patients (8 with ZollingerEllison syndrome, 3 with MEN-I syndrome), tumours were identified by octreotide scintigraphy in four patients (3 ZES, 1 MEN-I), which were confirmed by MR imaging in 3 patients (2 ZES, 1 MEN-I), and by CT in one patient with ZES. One patient with a long history of Zollinger-Ellison syndrome showed an abnormal increased octreotide uptake in the region of the head of the pancreas. This lesion was confirmed by MR imaging and CT scanning, and later a gastrinoma was proven at surgery ( Figure 2 ). In another 45-year-old patient with MEN-I syndrome, two primary tumours were found at surgery, one pancreatic, the other duodenal. Octreotide scintigraphy identified one tumour in the tail of the pancreas in a number of small lesions in the liver and multiple para-aortic lymph nodes. In another two patients with ZES, one patient had evidence of a tumour deposit in the tail of the pancreas on Octreoscan and the tumour was consequently cona b firmed at surgery; the other patient who had an metastatic lesions were found using any of these three imaging procedures.
However, more widespread disease: (4 liver lesions, 34 abdominal/mediastinal/peripheral lymph nodes, Lesions and 3 pancreatic sites) which was not suspected or identified by conventional imaging was recognized Altogether 42 tumour lesions were detected by CT and MR imaging. The distribution of these lesions by scintigraphy. Overall, the detection rate of octreotide scintigraphy was 91% of the liver lesions, 98% included liver (n=17) (multiple metastatic lesions in the liver were counted as one lesion), abdominal/ of lymph nodes, 100% of the lung, 89% of the pancreas and 30% of bone. The detection rate of mediastinal lymph node (n=6) (more than five sites were counted as five lesions, less than five sites were
[111In]-octreotide scintigraphy, MR imaging and CT scanning in localization of primary and metastatic counted as one lesion), lung (n=2), bone (n=10), and pancreas (n=7). Of the 42 localizations, 37 diseases in NET patients is summarized in Table 2 . The overall sensitivity, specificity, positive predictive were also identified by [111In]-octreotide scintigraphy. The five false-negative studies on Octreoscan were value (PPV) and negative predictive value (NPV) of Octreoscan were determined for each tumour type observed where the lesions occurred in liver (n=3), mediastinum (n=1) and bone (n=1), they were on the basis of the histological proof in Table 3 . However, the three patients with MCT were not from one carcinoid, one insulinoma and three MCTs. metastatic upper gastrointestinal tract neuroendo-(76.0%) patients had positive scintigraphy; while in crine tumour sites were detected with octreotide those over 60 years, 16/23 (69.9%) had positive scintigraphy (52%), with MR imaging (24%) and with scintigrams (p>0.05). Long-term somatostatin ana-CT scanning (36%); and by Carnaille et al.,15 in logues treatment did not appear to influence the which 72% of carcinoid tumour sites were identified outcome of the scintigram in our 12 patients who by Octreoscan. For the former, the lower detection had taken this therapy.
rate is probably because only tumours of the foregut type were studied, and the tumours were relatively Discussion small.30 Somatostatin receptor scintigraphy has been shown The great advantage of octreotide scintigraphy is to be useful in identifying primary tumours and that it can cover all body regions. Conventional distant metastases in most patients with NETs.
[111In]-imaging using CT or MRI will normally only examine octreotide scintigraphy was highly sensitive and areas of high clinical suspicion (e.g. thorax, upper specific for somatostatin-receptor positive tumours, abdomen, etc.). In a review, Lambert et al.13 especially in comparison with CT and MR scanning. described a group of 39 patients with gastroenteroIn our series, the sensitivity of octreotide scintigraphy pancreatic neuroendocrine tumours in which 37 for detecting carcinoid was 95%, and that for PET primary tumours and previously unknown metastases was 90.6%. This is therefore comparable to the 85% (95%) were detected by octreotide scintigraphy. In our 37 histologically-verified NETs, 50% of patients to 95% sensitivity reported in the literature.12-14 In had previously unexpected lesions detected (40 pre-11 ZES and MEN-I patients were also involved in this study. MEN-I is characterized by the familial viously unrecognized liver, mediastinal and extraassociation of parathyroid, pancreatic islet, and pituitabdominal lymph-node metastases being found). In ary hyperplasia or neoplasia.25 Parathyroid tumour this particular group, all two pancreatic, four liver and pancreatic islet-cell tumours are important fealesions and 11 lymph-node metastases were contures of MEN-I.26,27 Approximately 60% of islet-cell firmed, either by subsequent surgery or by biopsy. tumours in MEN-I patients secrete gastrin, resulting The remaining lesions will be followed-up by in the ZES which has been reported to be the cause Octreoscan or by conventional imaging methods.
of morbidity and mortality in this group of patients.28 However, in contrast to MR imaging, the detection Optimum therapy for MEN-I and ZES is the resection rate of Octreoscan in carcinoid bony metastases was of the primary tumour, and the control of the low in our series (30%).
symptoms due to hormone overproduction. The precondition for the accumulation of somatosTherefore, early identification and assessment of the tatin analogues in the scintigram is the presence of extent of tumour is becoming increasingly important. somatostatin receptors on the tumour cells. Using a
In the present study, the detection rate of patients receptor binding assay and in vitro autoradiography, potential role of this scintigraphy in detecting carciOur results from two insulinoma patients are consistnoids, pancreatic endocrine tumours, and medullary ent with these observations. Medullary carcinoma of thyroid tumours, as well as tumours in MEN-I and thyroid is known to bear somatostatin receptors at a ZES patients.
[111In]-octreotide scintigraphy has a relatively low level compared with other NETs. 21In
higher sensitivity for tumour detection, and it is our study, all three MCTs were false-negative on superior to MR imaging and CT scanning in identiscintigraphy. This may be explained by somatostatin fication of previously unsuspected extrahepatic and receptor negativity in the tumour tissues, or because lymph-node metastases. 
